FOR IMMEDIATE RELEASE
AVIVAGEN’S OXIMUNOL HELPS RAISE MONEY FOR THE ONTARIO VETERINARY COLLEGE’S NEW CANCER RESEARCH AND TREATMENT CENTRE
OTTAWA, ONTARIO, October 2, 2012 – Avivagen Inc. (TSXV:VIV), a wellness company, announced that it recently donated over 100 bottles of its Oximunol™ Chewables, a canine supplement that helps maintain healthy joint function and supports immune health, to support the 5th Annual Tomi Trial, a 3-day canine agility event that raised money for the Ontario Veterinary College (“OVC”) cancer research and treatment centre.
The agility event, which is held in honour of agility advocate and OVC supporter Tom Walker, was held at the Campaign Dog Academy in Georgetown, Ontario and attracted hundreds of pet lovers and agility enthusiasts alike.
Jennifer Lidbury, an agility instructor at the Campaign Dog Academy, helped organize the annual event. Jennifer considered the event to be a great success, “With more than 100 competitors over the 3-day span, we were able to raise a considerable amount of money to help support the OVC. And with so many great prizes almost everyone went home a winner!”
About Avivagen Inc.
Avivagen Inc., a wellness company, is developing and delivering products from its unique, proprietary OxC‐beta technology to assist in optimizing health and daily quality of life in animals and humans. Avivagen Inc. has commercialized its first product for the companion animal market, Oximunol™ Chewables for dogs, and is advancing product candidates in the food animal market and for potential human applications. More information can be found at
Forward Looking Statements
This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “will”, "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions. The forward-looking statements reflect the current expectations of Avivagen Inc. regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For more information:
David HankinsonGraham Burton, PhD
CEO, Avivagen Inc.President and Co-Founder, Avivagen Inc.
Phone: 902-825-9270Phone: 613-990-0969